Caxton Associates LLP Grows Holdings in Cencora, Inc. $COR

Caxton Associates LLP increased its stake in Cencora, Inc. (NYSE:COR) by 41.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,634 shares of the company’s stock after buying an additional 3,114 shares during the period. Caxton Associates LLP’s holdings in Cencora were worth $3,189,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in COR. Kovitz Investment Group Partners LLC increased its position in shares of Cencora by 9.3% in the 1st quarter. Kovitz Investment Group Partners LLC now owns 3,513 shares of the company’s stock worth $977,000 after purchasing an additional 299 shares during the last quarter. Horizon Investments LLC grew its stake in Cencora by 3.6% in the first quarter. Horizon Investments LLC now owns 2,496 shares of the company’s stock worth $694,000 after purchasing an additional 86 shares in the last quarter. Ethic Inc. increased its holdings in Cencora by 2.4% in the first quarter. Ethic Inc. now owns 9,769 shares of the company’s stock valued at $2,710,000 after buying an additional 233 shares during the last quarter. Steward Partners Investment Advisory LLC raised its stake in Cencora by 1.0% during the first quarter. Steward Partners Investment Advisory LLC now owns 53,475 shares of the company’s stock valued at $14,871,000 after buying an additional 507 shares in the last quarter. Finally, Aviso Financial Inc. lifted its holdings in Cencora by 17.5% during the 1st quarter. Aviso Financial Inc. now owns 8,769 shares of the company’s stock worth $2,439,000 after buying an additional 1,305 shares during the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the sale, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. The trade was a 11.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 46,640 shares of company stock worth $14,099,338. 10.80% of the stock is owned by corporate insiders.

Cencora Price Performance

NYSE COR opened at $345.86 on Monday. The company has a 50-day moving average price of $343.29 and a two-hundred day moving average price of $311.48. Cencora, Inc. has a 52 week low of $223.92 and a 52 week high of $377.54. The stock has a market cap of $67.09 billion, a price-to-earnings ratio of 43.50, a price-to-earnings-growth ratio of 1.64 and a beta of 0.63. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. During the same quarter in the previous year, the company posted $3.34 earnings per share. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were given a $0.60 dividend. The ex-dividend date was Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is currently 30.19%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on COR shares. TD Cowen boosted their price target on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. Robert W. Baird lifted their price target on shares of Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Cencora in a research note on Monday, December 8th. UBS Group lifted their target price on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Finally, Wells Fargo & Company upped their target price on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and an average target price of $373.50.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.